OnKure Therapeutics Appoints Jennifer R. Diamond, M.D., as Chief Medical Officer

OnKure Therapeutics任命Jennifer R.Diamond医学博士为首席医疗官

2021-10-14 22:30:07 BioSpace


BOULDER, Colo.---- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Jennifer R. Diamond, M.D., as Chief Medical Officer. Dr. Diamond, a trained oncologist, brings over 10 years of extensive clinical expertise in early phase trials and translational oncology research. “We are very pleased to welcome Jennifer to our growing leadership team,” said Tony Piscopio, Ph.D., Co-Founder, President and Chief Executive Officer of OnKure. “Her vast knowledge of conducting early-stage trials for novel oncology therapeutics, as well as her experience exploring novel combination strategies, will be vital as we continue to build and advance our broad pipeline of best-in-class precision medicines.” In addition to serving in her role at OnKure, Dr. Diamond works in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus as a breast cancer medical oncologist and Associate Professor of Medicine. She is also the Clinical Research Director of the Phase 1 and Expansion/Molecular Studies Program (POEMs) and the founding Co-Director of the Women’s Cancer Developmental Therapeutics Program at the CU Cancer Center. Dr. Diamond has been involved in clinical and translational research in the Phase 1 and Breast Cancer research programs at CU since 2007 and currently runs a research laboratory focused on the development of targeted agents in TNBC, including strategies to overcome treatment resistance. She received her B.A. from the University of Arizona and her M.D. from the University of Arizona College of Medicine. Dr. Diamond completed her fellowship in Medical Oncology at CU under Dr. Gail Eckhart. “I am thrilled to be joining OnKure at such an important time in the Company’s growth,” said Dr. Diamond. “OnKure’s proven structure-based drug design approach has the potential to create optimal, tumor-agnostic treatments for cancer patients with high unmet need. I look forward to leveraging my experiences to lead the Company’s clinical development efforts and advance its promising lead candidate, OKI-179, as well as future oncology programs in the clinic.” About OnKure Therapeutics OnKure, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer. Using its proven structure-based drug design approach, the Company is building a robust pipeline of tumor-agnostic candidates that are designed to achieve optimal tolerability and efficacy. OnKure is currently developing its lead clinical candidate, OKI-179, an oral, selective Class 1 HDAC inhibitor, for the treatment of both hematological and solid tumors, with plans to initiate a Phase 2 combination trial with binimetinib in NRAS melanoma in 2022. For more information about OnKure, please visit www.onkuretherapeutics.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005296/en/ Media: Julia Deutsch Solebury Trout jdeutsch@soleburytrout.com Source: OnKure, Inc. View this news release online at: http://www.businesswire.com/news/home/20211014005296/en
科罗拉多州博尔德----OnKure公司,一家临床阶段的生物制药公司,发现和开发下一代肿瘤精确药物,今天宣布任命詹妮弗·R·戴蒙德医学博士为首席医疗官。戴蒙德博士是一位训练有素的肿瘤学家,在早期试验和转化肿瘤学研究方面拥有超过10年的广泛临床专业知识。 Onkure联合创始人、总裁兼首席执行官托尼·皮斯科皮奥博士说:“我们非常高兴地欢迎珍妮弗加入我们不断壮大的领导团队。”“她在进行新型肿瘤治疗早期试验方面的丰富知识,以及她探索新型组合策略的经验,将对我们继续建设和推进一流精准药物的广泛管道至关重要。” 除了在OnKure任职之外,戴蒙德博士还在科罗拉多大学安舒茨医学院的医学肿瘤学部门担任乳腺癌医学肿瘤学家和医学副教授。她也是第一阶段和扩展/分子研究项目(POEMs)的临床研究主任,以及CU癌症中心妇女癌症发育治疗项目的创始联合主任。Diamond博士自2007年以来一直参与CU第一阶段和乳腺癌研究项目的临床和转化研究,目前经营着一个研究实验室,专注于TNBC靶向药物的开发,包括克服治疗耐药性的策略。她获得了学士学位。亚利桑那大学和她的医学博士。来自亚利桑那大学医学院。戴蒙德博士在盖尔·埃克哈特博士的指导下完成了她在CU的医学肿瘤学研究金。 戴蒙德博士说:“我很高兴能在公司发展的如此重要的时刻加入昂库雷。”“Onkure经过验证的基于结构的药物设计方法有潜力为那些需求高而未得到满足的癌症患者创造最佳的、与肿瘤无关的治疗方法。我期待着利用我的经验来领导公司的临床开发工作,并推进其有前途的领先候选人OKI-179以及临床未来的肿瘤学项目。“ 关于OnKure疗法 OnKure公司是一家临床阶段的生物制药公司,专注于发现和开发针对生物学验证的癌症驱动因素的同类最佳精准药物。利用其经过验证的基于结构的药物设计方法,该公司正在建立一个强大的肿瘤未知候选管道,旨在实现最佳的耐受性和疗效。OnKure目前正在开发其主要临床候选药物OKI-179,这是一种口服的选择性1类HDAC抑制剂,用于治疗血液肿瘤和实体瘤,计划在2022年启动与比尼美替尼联合治疗NRAS黑色素瘤的2期试验。 有关OnKure的更多信息,请访问www.onkuretherapeutics.com。 在businesswire.com查看源代码版本:https://www.businesswire.com/news/home/20211014005296/en/ 媒体: 朱莉娅·多伊奇 索尔伯里鳟鱼 jdeutsch@soleburytrout.com 资料来源:OnKure公司。 在网上查看此新闻稿: http://www.businesswire.com/news/home/20211014005296/en